What drug is Asiminib? What does it do?

Asciminib (Asciminib) is a new type of tyrosine kinase inhibitor (TKI) used to treat a specific type of chronic myelogenous leukemia (CML). It is the first drug designed based on the BCR-ABL target discovered by "STI571" (imatinib) and focusing on the ABL myristoyl pocket (STAMP) mechanism. Different from traditional TKI, aceminib binds to the unique position of BCR-ABL fusion protein, thereby achieving the inhibition of this pathological signaling pathway. This mechanism gives it therapeutic potential for patients with drug-resistant mutations, especially the T315I mutation. Aceminib shows high specificity in the treatment of chronic myelogenous leukemia, reducing the impact on normal cells, thus reducing some of the side effects of traditional TKI drugs. Its clinical development is mainly aimed at patients who have received multiple TKI treatments in the past but had poor efficacy or developed drug resistance. In addition, aceminib has proven its safety and efficacy in multiple international clinical trials and is regarded as an important new treatment option.